Coya Therapeutics (COYA) Stock Price, News & Analysis

Company Overview

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies designed to enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune responses and may play a role in limiting inflammation associated with neurodegenerative and autoimmune diseases.

The company’s pipeline includes investigational Treg-based therapies, including COYA 301, an autologous Treg therapy being evaluated for potential use in conditions such as amyotrophic lateral sclerosis (ALS). Coya is also developing combination approaches intended to improve Treg activity and persistence, including programs involving low-dose interleukin-2. Its candidates remain experimental and are subject to clinical and regulatory evaluation.

Headquartered in Houston, Texas, Coya Therapeutics became a publicly traded company through a business combination with Nicoya Healthcare in 2023. The company’s development strategy is centered on advancing its proprietary Treg-focused platform for diseases in which chronic inflammation and impaired immune regulation may contribute to disease progression.

Key Stats

• Today's Range: $4.70 to $5.00
• 50-Day Range: $3.87 to $5.30
• 52-Week Range: $3.71 to $7.75
• Volume: 116,133 shs
• Average Volume: 181,004 shs
• Market Capitalization: $110.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.33
• Consensus Rating: Moderate Buy

Coya Therapeutics Stock Analysis - MarketRank™

Coya Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 622nd out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Coya Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Coya Therapeutics has a consensus price target of $15.33, representing about 214.9% upside from its current price of $4.87.

Amount of Analyst Coverage

Coya Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Coya Therapeutics are expected to decrease in the coming year, from ($1.34) to ($1.92) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Coya Therapeutics is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Coya Therapeutics is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Coya Therapeutics has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.39% of the float of Coya Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Coya Therapeutics has a short interest ratio ("days to cover") of 10.24, which indicates bearish sentiment.

Change versus previous month

Short interest in Coya Therapeutics has recently increased by 9.41%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Coya Therapeutics does not currently pay a dividend.

Dividend Growth

Coya Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Coya Therapeutics has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Coya Therapeutics this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added Coya Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Coya Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.10% of the stock of Coya Therapeutics is held by insiders.

Percentage Held by Institutions

39.75% of the stock of Coya Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/01/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:COYA
• CIK: 1835022
• Web: www.coyatherapeutics.com
• Phone: (650) 739-3939
• Fax: N/A
• Employees: 8
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Coya Therapeutics: $15.33
• High Price Target: $18.00
• Low Price Target: $12.00
• Potential Upside/Downside: +223.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.23 million
• Net Margins: -270.22%
• Pretax Margin: -270.18%
• Return on Equity: -52.05%
• Return on Assets: -46.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.40
• Quick Ratio: 13.40

Sales & Book Value

• Annual Sales: $7.95 million
• Price / Sales: 13.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.06 per share
• Price / Book: 2.30

Miscellaneous

• Outstanding Shares: 23,460,000
• Free Float: 22,027,000
• Market Cap: $111.20 million
• Optionable: Not Optionable
• Beta: 0.61